Amine-based carbon dioxide adsorbent resistant to oxygen and sulfur dioxide and method of preparing the same

    公开(公告)号:US10654025B2

    公开(公告)日:2020-05-19

    申请号:US16191527

    申请日:2018-11-15

    Abstract: The core-shell type amine-based carbon dioxide adsorbent including a chelating agent resistant to oxygen and sulfur dioxide according to the present invention is an adsorbent which includes a chelating agent to inhibit oxidative decomposition of amine and has, as a core, a porous support on which an amine compound is immobilized and has, as a shell, an amine layer resistant to inactivity by sulfur dioxide, and a method of preparing the same. The amine-based carbon dioxide adsorbent including a chelating agent exhibits considerably high oxidation resistance because an added chelate compound functions to directly remove a variety of transition metal impurities catalytically acting on amine oxidation. In addition, the sulfur dioxide-resistant amine layer of the shell selectively adsorbs sulfur dioxide to protect the amine compound of the core and, at the same time, the amine compound of the core selectively adsorbs only carbon dioxide. In addition, sulfur dioxide adsorbed on the shell is readily desorbed therefrom at about 110° C. and thus remarkably improved regeneration stability is obtained during the temperature-swing adsorption (TSA) process containing sulfur dioxide.

    CONJUGATE OF VEGF-GRAB PROTEIN AND DRUG, AND USE THEREOF

    公开(公告)号:US20200148757A1

    公开(公告)日:2020-05-14

    申请号:US16625707

    申请日:2018-07-02

    Abstract: The present invention relates to a VEGF-Grab protein-drug conjugate and a use thereof and, more particularly, to a conjugate of a fusion protein in which a VEGFR1 domain 2, a VEGFR1 domain 3, and an antibody fragment are connected and a drug, a pharmaceutical composition for prevention or treatment of cancer or angiogenesis-related disease, comprising the conjugate, and a method for prevention or treatment of cancer or angiogenesis-related disease. Serving as a multi-paratopic VEGF decoy receptor, the conjugate including a VEGF-Grab protein and a drug of the present invention can be used as a multi-purpose platform for treatment of cancer or angiogenesis-related disease.

    WIDEBAND VARIABLE GAIN AMPLIFIER WITH LOW PHASE VARIATION

    公开(公告)号:US20200144978A1

    公开(公告)日:2020-05-07

    申请号:US16215864

    申请日:2018-12-11

    Abstract: A wideband variable gain amplifier (VGA) having a low phase change is disclosed. The first VGA amplifies an input signal by a current steering manner so that an amplification gain is variable. The larger a variable gain amount of the first output signal amplified by the first VGA is, the more a relative phase change amount gradually increases in either positive direction or negative direction. The second VGA further amplifies the first amplified output signal in the current steering manner so as to vary the amplification gain. As a variable gain amount of a second output signal amplified by the second VGA becomes larger, a relative phase change amount gradually increases in a direction opposite to the phase change direction of the first VGA. This opposing phase changes of the first and second VGAs are canceled against each other to provide a variable amplification gain over the wideband frequency range with a low phase change.

Patent Agency Ranking